DELIVER Therapeutics, Inc. is leveraging high-throughput DNA encoded library (DEL) drug screening to develop innovative small molecule therapeutics aimed at addressing significant clinical challenges, particularly in oncology. The company has identified a library of 7 billion compounds to discover best-in-class new chemical entities (NCEs) that target key tyrosine kinases associated with various cancers, including ABL1 and its resistant mutants. Their lead product candidate, DTC-0220, is a multi-kinase inhibitor designed to treat Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ ALL) and similar conditions. This compound demonstrates remarkable efficacy, with single nM IC50s against multiple kinases, including ABL1-T315I, and shows up to 15-fold greater effectiveness against certain patient-derived tumor cell lines compared to the currently approved treatment, ponatinib.

In addition to their oncology focus, DELIVER Therapeutics is also addressing the challenges posed by cellular senescence and its associated inflammatory response, known as the senescence-associated secretory phenotype (SASP). The company is developing selective JAK2 and JAK3 inhibitors that aim to modulate the SASP without the adverse effects linked to JAK1 inhibition. By targeting the JAK/STAT pathway, these therapies are intended to mitigate chronic inflammation and its detrimental effects on aging and age-related diseases. Overall, DELIVER Therapeutics is committed to pioneering first-in-class and best-in-class small molecule candidates that can significantly improve patient outcomes in both cancer and age-related conditions.

United States

Applying novel, high throughput screening technologies to deliver therapeutics that address the most difficult problems in clinical medicine

DELIVER Therapeutics, Inc.

Company Details